Back to Results
First PageMeta Content
Companies listed on the New York Stock Exchange / Medicis Pharmaceutical / Regulation S-K / Food and Drug Administration / Restylane / Form 10-K / Acne vulgaris / Minocycline / Sulfacetamide/sulfur / Medicine / SEC filings / Anti-acne preparations


2010 MEDICIS
Add to Reading List

Document Date: 2013-03-21 10:42:00

Open Document

File Size: 2,05 MB

Share Result on Facebook

Company

U.S. We / MEDICIS PHARMACEUTICAL CORPORATION / Business The Company Medicis Pharmaceutical Corporation / Medicis Technologies Corporation / Center for Research in Security Prices / CRSP NYSE Stock Market / NYSE Pharmaceutical / LipoSonix Inc. / New York Stock Exchange / /

Continent

North America / Europe / /

Country

United States / Canada / /

Currency

SGD / USD / /

Event

FDA Phase / M&A / General or Shareholder Meeting / Patent Issuance / /

Facility

The University of Chicago / /

IndustryTerm

dermatology product / treatment of urea cycle disorders / pharmaceutical development process / dermatological pharmaceutical sales / corporate Web site / excellent products / dermatological products / non-invasive body sculpting technology / immediate release minocycline products / chemical entities / medical device company developing non-invasive body sculpting technology / owned subsidiaries / investigational device / prescription pharmaceutical products / pharmaceutical company focusing / /

MedicalCondition

inflammatory and pruritic manifestations / urea cycle disorders / hyperpigmentation / acne vulgaris / psoriasis / fungal infections / corticosteroid responsive dermatoses / acne / rosacea / severe acne vulgaris / inflammatory lesions / seborrheic dermatitis / /

MedicalTreatment

RESTYLANE / plastic surgery / /

Organization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington / D.C. / U.S. Patent and Trademark Office / Graduate School / The University of Chicago / I.R.S. / FDA / American Society for Aesthetic Plastic Surgery / /

Person

Jonah Shacknai / /

/

Position

Chairman and Chief Executive Officer / Director Independence / /

Product

clindamycin phosphate / Extended Release Tablets / DYNACIN / SOLODYN / ciclopirox / AMMONUL / tretinoin / fluocinonide / sodium sulfacetamide / BUPHENYL / ZIANA / HCl Tablets / Lidocaine / LOPROX / VANOS / PERLANE-L® / RESTYLANE / extended / SOLODYN® / launched / Approved Drug / PERLANE® RESTYLANE / PERLANE / RESTYLANE-L® / AMMONUL® / /

ProvinceOrState

Delaware / /

Technology

medical device company developing non-invasive body sculpting technology / non-invasive body sculpting technology / /

SocialTag